1. Home
  2. PROP vs CGTX Comparison

PROP vs CGTX Comparison

Compare PROP & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prairie Operating Co.

PROP

Prairie Operating Co.

HOLD

Current Price

$1.10

Market Cap

105.6M

Sector

Finance

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

110.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROP
CGTX
Founded
2001
2007
Country
United States
United States
Employees
N/A
14
Industry
Investment Bankers/Brokers/Service
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
105.6M
110.8M
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
PROP
CGTX
Price
$1.10
$1.23
Analyst Decision
Buy
Strong Buy
Analyst Count
5
3
Target Price
$6.75
$3.33
AVG Volume (30 Days)
5.4M
991.1K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
49.06
62.79
EPS
N/A
N/A
Revenue
$7,939,000.00
N/A
Revenue This Year
$81.83
N/A
Revenue Next Year
$18.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
413.59
N/A
52 Week Low
$1.08
$0.22
52 Week High
$4.68
$3.83

Technical Indicators

Market Signals
Indicator
PROP
CGTX
Relative Strength Index (RSI) 36.17 56.53
Support Level N/A $1.19
Resistance Level $1.93 $1.36
Average True Range (ATR) 0.09 0.10
MACD 0.01 0.00
Stochastic Oscillator 6.52 53.57

Price Performance

Historical Comparison
PROP
CGTX

About PROP Prairie Operating Co.

Prairie Operating Co is a Houston-based independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company's assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: